Biocon Secures Yesintek Market Entry in Additional Global Markets
Biocon said it secured market entry for Yesintek, a proposed biosimilar to Stelara, in additional global markets. It said it inked a licence agreement with Janssen Sciences Ireland.
Biocon said it secured market entry for Yesintek, a proposed biosimilar to Stelara, in additional global markets. It said it inked a licence agreement with Janssen Sciences Ireland.